Eptifibatide 20mg/10ml solution for injection vials
Requires a prescription from a doctor or prescriber
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Eptifibatide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Eptifibatide
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Eptifibatide on the MHRA register
Eptifibatide 20mg/10ml solution for injection vials
WHO defined daily dose (DDD)
200 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Eptifibatide
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(2)
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
44 found
Half-life
2.5 hours
Mechanism
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet…
Food interactions
1 warning
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
2.5 hours
Protein binding
25%
Metabolism
Clearance
55 mL
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 419 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain (By similarity). Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen .
PMID:9111081
This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity).
ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling .
PMID:23125415 PMID:24789099
ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling .
PMID:20682778
ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling .
PMID:18441324
ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling .
PMID:28302677
ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling .
PMID:19578119
ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling .
PMID:28873464
ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling .
PMID:29030430
ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 .
PMID:18635536 PMID:25398877
ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 .
PMID:12807887
In brain, plays a role in synaptic transmission and plasticity. Involved in the regulation of the serotonin neurotransmission, is required to localize to specific compartments within the synapse the serotonin receptor SLC6A4 and for an appropriate reuptake of serotonin. Controls excitatory synaptic strength by regulating GRIA2-containing AMPAR endocytosis, which affects AMPAR abundance and composition (By similarity).
ITGAV:ITGB3 act as a receptor for CD40LG .
PMID:31331973
ITGAV:ITGB3 acts as a receptor for IBSP and promotes cell adhesion and migration to IBSP PMID:10640428
Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen .
PMID:9111081
This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface (By similarity)
They are involved in pain signaling .
PMID:25296916
Calcium channels containing alpha-1B subunit may play a role in directed migration of immature neurons. Mediates Ca(2+) release probability at hippocampal neuronal soma and synaptic terminals (By similarity)
ATC B01AC16
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Eptifibatide
Additional database identifiers
Drugs Product Database (DPD)
11891
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6156
GenAtlas
ITGB3
GeneCards
ITGB3
GenBank Gene Database
J02703
GenBank Protein Database
306786
Guide to Pharmacology
2457
UniProt Accession
ITB3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6138
GenAtlas
ITGA2B
GeneCards
ITGA2B
GenBank Gene Database
J02764
GenBank Protein Database
190068
Guide to Pharmacology
2441
UniProt Accession
ITA2B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1399
GenAtlas
CACNA2D1
GeneCards
CACNA2D1
GenBank Gene Database
M76559
GenBank Protein Database
179762
UniProt Accession
CA2D1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1400
GenAtlas
CACNA2D2
GeneCards
CACNA2D2
GenBank Gene Database
AJ251368
UniProt Accession
CA2D2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1389
GenAtlas
CACNA1B
GeneCards
CACNA1B
GenBank Gene Database
M94172
GenBank Protein Database
179758
Guide to Pharmacology
533
UniProt Accession
CAC1B_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
All patents expired, 3 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: